Clinical Trials Logo
  1. Home
  2. Psoriasis Vulgaris
  3. NCT02796053

TAB08 in Patients With Psoriasis Vulgaris, Not Adequately Controlled With Current Treatment

Psoriasis Vulgaris Clinical Trial

Official title:
Study to Assess Pharmacodynamics, Clinical Effects, Safety and Pharmacokinetics of TAB08 in Patients With Psoriasis Vulgaris, Not Adequately Controlled With Current Concomitant Therapy

Clinical Trial Summary

Study to assess Pharmacodynamics, Safety, Pharmacokinetics and clinical effects of TAB08 during 12 weeks of treatment in patients with Psoriasis Vulgaris, not adequately controlled with current therapy.

Clinical Trial Description

1. To assess dynamics of the T-lymphocytes subpopulations in patients peripheral blood during 12 weeks of TAB08 treatment.

2. To assess dynamics of selected cytokines levels in patients peripheral blood during 12 weeks of TAB08 treatment.

3. To assess TAB08 concentrations in patients blood during 12 weeks of TAB08 treatment.

4. To assess frequency, seriousness and severity of adverse events during 12 weeks of TAB08 treatment.

5. To assess changes in PASI, IGA and DLQI during 12 weeks of TAB08 treatment and subsequent 4 weeks follow-up. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT02796053
Study type Interventional
Source Theramab LLC
Contact
Status Completed
Phase Phase 1/Phase 2
Start date April 2016
Completion date December 2016
View Details
See also
  Status Clinical Trial Phase
Completed NCT03669757 - Clinical Trial to Assess Safety, Tolerability and the Pharmacodynamic Effect of Different Concentrations of a New Anti-inflammatory Substance in Subjects With Chronic Plaque Psoriasis Phase 1
Completed NCT03614078 - A Study of PRCL-02 in Moderate to Severe Chronic Plaque Psoriasis Phase 2
Completed NCT03584360 - Role of Topical Treatments in the Modulation of Skin Microbiome in Psoriatic Skin Phase 2
Recruiting NCT04994951 - Pilot Study of Traditional Chinese Medicine (Qing-Re-Liang-Xue Decoction) as Complementary Medicine for Psoriasis Vulgaris of Blood-heat Syndrome. Phase 2
Completed NCT02888236 - LEO 32731 for the Treatment of Moderate to Severe Psoriasis Vulgaris Phase 2
Completed NCT02533973 - Long-term Treatment of Scalp Psoriasis With Xamiol® Gel in a Large Adult Chinese Population Phase 4
Completed NCT02193815 - A 12 Day Study To Evaluate A Topical Drug To Treat Plaque Psoriasis Phase 1
Completed NCT01946386 - A Vasoconstriction Study With LEO 90100 Phase 1
Completed NCT02004847 - Blue Light for Treating Psoriasis Vulgaris N/A
Recruiting NCT01443338 - Study Evaluating the Efficacy and Safety of Triptergium Wilfordii and Acitretin in Psoriasis Vulgaris - CHINA201002016-2 Phase 4
Completed NCT01188928 - LEO 80185 in the Treatment of Psoriasis Vulgaris on the Non-scalp Regions of the Body (Trunk and/or Limbs) Phase 3
Completed NCT00764751 - Efficacy and Safety of LEO 19123 Cream in the Treatment of Psoriasis Vulgaris Phase 2
Completed NCT00236171 - Evaluation of Topical Antipsoriatics in the Psoriasis Plaque Test N/A
Completed NCT04541329 - Predicting Inflammatory Skin Disease Response to IL-23 Blockade Phase 4
Completed NCT06064084 - Incretin Effect in Patients With Psoriasis and Controls
Not yet recruiting NCT06398106 - Proactive TDM Versus Standard Use of Biologics in Psoriasis Phase 4
Recruiting NCT05390515 - Psoriatic Immune Response to Tildrakizumab Phase 4
Recruiting NCT05892640 - Low-Salt Diet Effect on Th17-Mediated Inflammation and Vascular Reactivity in Psoriasis N/A
Recruiting NCT04950218 - The Psoriasis Echo Study
Completed NCT05184348 - Plexin B2 Gene Expression and Polymorphisms in Psoriasis Phase 1